Retatrutide, a experimental dual activator of the GLP-1 target and glucose-dependent released polypeptide (GIP) target, is exhibiting promising results in preliminary patient trials . Ongoing research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/